Dr. Kurtz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsGenetic alteration of class I HLA in cutaneous T-cell lymphoma.Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li
Blood. 2025-01-16 - 9 citationsCAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.Mark P Hamilton, Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis
Blood Advances. 2024-06-25 - 4 citationsQuantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.Tej D Azad, Shigeki Nanjo, Michael C Jin, Jacob J Chabon, David M Kurtz
NPJ Precision Oncology. 2024-05-28
Abstracts/Posters
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell LymphomaDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel TherapyDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-cell LymphomaJanuary 16th, 2025- NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-cell LymphomaJanuary 10th, 2025
- Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma PatientsDecember 5th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
